richard_scheller

23andMe assigns chief scientific officer to new unit

pharmafile | March 17, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |  23andm3, Richard Scheller 

US personal genetics firm 23andMe has created a new therapeutics group and appointed pharma veteran Richard Scheller as chief science officer and head of therapeutics to lead it.

Scheller retired in December 2014 from a 14-year career as an executive at Genentech, where he was the executive vice president of its research and early development business.  

Scheller also served on the faculty of Stanford University for 19 years as a professor in the Department of Biological Sciences and the Department of Molecular and Cellular Physiology, and was an investigator at the Howard Hughes Medical Institute of Stanford University Medical Center.

Advertisement

He also serves as an adjunct professor in the Department of Biochemistry and Biophysics at the University of California, San Francisco, and has published more than 280 research studies.

“With Dr Scheller joining the team, we are putting significant resources into translating genetic information into the discovery and development of new therapies for our customers and the world,” says 23andMe chief executive and co-founder Anne Wojcicki.  

Scheller adds: “I have dedicated my life to research aimed at fulfilling unmet needs for very sick people. I believe that human genetics has a very important role to play in finding new treatments for disease. I am excited about the potential for what may be possible through 23andMe’s database. It is unlike any other.”

Related Content

No items found
The Gateway to Local Adoption Series

Latest content